Weekly dose of osteoporosis drug prevents bone loss after breast cancer treatmentSeptember 19, 2007Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research. Scientific sessions continue through Wednesday at the Hawaii Convention Center. Susan Greenspan, M.D., director of the Osteoporosis Prevention and Treatment Center and Bone Health program at the University of Pittsburgh Medical Center, and colleagues evaluated 87 women, mean age 50, enrolled in the Prevention of Osteoporosis in Postmenopausal Women with Breast Cancer Following Chemotherapy study. All participants in the randomized, double-blind trial received calcium and vitamin D supplements. However, half took 35 milligrams of risedronate once a week while others took a placebo. "Chemotherapy drugs and other medical treatments for breast cancer are known to induce menopause, which can kick-start bone loss, putting survivors at risk for osteoporotic fractures," said Dr. Greenspan, an internationally respected osteoporosis researcher and professor of medicine at Pitt. "This study also looked at changes in spine and hip bone mineral density, as well as evidence of bone breakdown."
Ninety-seven percent of study participants had normal or low bone mass at enrollment. At baseline, many were taking tamoxifen, a breast cancer drug aimed at estrogen-sensitive tumors that also is sometimes used as a preventive therapy by women at high risk for breast cancer. While tamoxifen can have a positive impact on bone in postmenopausal women, a small percentage of women were taking aromatase inhibitors (also used for prevention), which can have a negative effect on bone. During the second year of the study, about half the women began taking aromatase inhibitors and stopped taking tamoxifen. "After 24 months, women in the placebo group had significant bone loss in the spine and hip that we didn't see in women taking risedronate," noted Dr. Greenspan. "In fact, women taking risedronate had a bone density much higher in the spine and hip than women in the placebo group." The researchers also observed that the greatest bone loss was found in women on aromatase inhibitors. Even so, risedronate continued to be successful in preventing bone loss. "We conclude that once weekly doses of risedronate improves bone density and prevents excess bone loss in breast cancer survivors," the researchers noted. University of Pittsburgh Schools of the Health Sciences | |||||||||||||||||||||
|
Related Breast Cancer Current Events and Breast Cancer News Articles Hormone therapy associated with reduced colorectal cancer risk The combination of estrogen plus progestin, which women stopped taking in droves following the news that it may increase their risk of breast cancer, may decrease their risk of colorectal cancer, according to a report published in the January issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research. Team finds breast cancer gene linked to disease spread A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death. Dormant cancer cells rely on cellular self-cannibalization to survive A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation. How to enhance non-thermal effects of ultrasound In recent years HIFU has been widely used for the treatment of solid tumors, such as liver tumor, bone tumor, and breast cancer. The mechanism for therapeutic actions of HIFU includes thermal effects and non-thermal effects with the latter dominated by cavitational effects. Obesity Increases Lymphedema Risk for Breast Cancer Survivors Throughout the world, 10 million breast cancer survivors have a lifetime risk for developing lymphedema, a chronic condition that involves swelling of the limbs and impacts physical and psychosocial health. Researchers compile 'molecular manual' for 100s of inherited diseases An international research team has compiled the first catalogue of tissue-specific pathologies underlying hundreds of inherited diseases. Modified gene targets cancer cells a thousand times more often than healthy cells Researchers at the University of Rochester have designed a gene that produces a thousand times more protein in cancer cells than in healthy cells. Meta-analyses of global trials finds in favor of aromatase inhibitors Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. Interactive gene 'networks' may predict if leukemia is aggressive or slow-growing Rather than testing for individual marker genes or proteins, researchers at the University of California, San Diego (UC San Diego) and the Moores UCSD Cancer Center have evidence that groups, or networks, of interactive genes may be more reliable in determining the likelihood that a form of leukemia is fast-moving or slow-growing. Confusing risk information may lead to poor cancer treatment choices A new study from researchers at the University of Michigan Comprehensive Cancer Center found that a tool commonly used by doctors to estimate the risk of a woman's breast cancer returning after surgery is not very effective at explaining risk to patients. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||